http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013542259-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2011-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2013542259-A |
| titleOfInvention | Substituted azaindazole compounds |
| abstract | Formula (I): (I) Wherein Q is: (i) a 5-membered heteroaryl containing at least one nitrogen heteroatom and substituted with 0-2 R g ; or (ii) A 9 or 10 membered bicyclic heteroaryl selected from wherein Ring A is a 5 or 6 membered aryl or heteroaryl fused ring substituted with 0 to 2 R g ; R 1 , R 2 , R 3 and R g are as defined herein], an azaindazole compound or a pharmaceutically acceptable salt thereof is disclosed. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 related disease (eg, cancer) and pharmaceutical compositions comprising such compounds. |
| priorityDate | 2010-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 271.